Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating

Lisa A Lesniewski1,2,3, Douglas R Seals4, Ashley E Walker1

  • 1Division of Geriatrics, Department of Internal Medicine, Salt Lake City, UT, USA.

Aging Cell
|September 24, 2016
PubMed

Insights

Rapamycin treatment improved arterial aging in old mice by reducing oxidative stress and arterial stiffness. This intervention enhanced endothelium-dependent dilation and normalized senescence markers, suggesting potential benefits for cardiovascular health.

Area of Science:

  • Gerontology and Cardiovascular Science
  • Molecular Biology and Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) inhibition is known to extend lifespan and reduce age-related diseases.
  • The specific role of mTOR in arterial aging and the potential of dietary rapamycin to ameliorate age-related arterial dysfunction remain largely unexplored.

Purpose of the Study:

  • To investigate the role of mTOR in the arterial aging phenotype.
  • To determine if dietary rapamycin can improve age-related arterial dysfunction in mice.

Main Methods:

  • Young and old male mice were fed either a rapamycin-supplemented or a control diet for 6-8 weeks.
  • Assessed arterial function, including endothelium-dependent dilation (EDD) and aortic pulse-wave velocity (PWV).
  • Measured oxidative stress markers (superoxide production, NADPH oxidase expression), mTOR activation (S6K phosphorylation), AMPK activation, and senescence markers (p19).

Main Results:

  • Rapamycin treatment reversed age-related increases in mTOR activation and improved EDD in old mice.
  • Rapamycin normalized elevated superoxide production and NADPH oxidase expression in arteries of old mice.
  • In old mice, rapamycin reduced aortic stiffness (PWV), collagen content, and arterial senescence marker p19, while increasing AMPK phosphorylation.

Conclusions:

  • Dietary rapamycin demonstrates beneficial effects on arterial function in aging mice.
  • Improvements in arterial health are associated with reduced oxidative stress, enhanced AMPK activation, and modulation of cell cycle proteins.
  • These findings suggest rapamycin as a potential therapeutic strategy for mitigating age-related arterial dysfunction.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
787
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
308
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
295
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
4.1K